Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.
Quick Facts
Reference Sizes
1 g, 5 g, 10 g
Storage
No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data
Solubility
Poorly water-soluble; dissolve with Vitamin C or quercetin phytosome/liposomal forms for better bioavailability
Best-Effort Research Profile
Quercetin is a plant flavonoid studied for senolytic activity, most notably as part of the dasatinib-plus-quercetin (D+Q) combination - among the first senolytic regimens tested in early-phase human trials for conditions including idiopathic pulmonary fibrosis and diabetic kidney disease. As a standalone agent, quercetin also has documented antioxidant and anti-inflammatory properties from a broader nutrition literature base.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Research Profile
Half-Life
Variable, generally short with limited bioavailability as an isolated flavonoid
Onset
Early-phase D+Q trials have assessed intermittent (periodic) dosing schedules
Administration Routes (Research)
Oral
Reported Research Effects
Senolytic activity, primarily studied in combination with dasatinib (D+Q)
Antioxidant and anti-inflammatory properties
Reported Research Side Effects
Human safety, pharmacokinetics, and interaction data are incomplete
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Route-Specific Research Protocols
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Label / guidelineHuman studyCommunity onlyPreclinical onlyNot established
OralHuman study only
500-1000 mg/day in heterogeneous supplement trials
Frequency / timing
Daily
Duration / setting
Study-specific
Technique
Oral
Evidence
Human study protocol
Context: systematic-review evidence
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Research Notes
The dasatinib-plus-quercetin senolytic regimen is investigational and must not be presented as a quercetin supplement stack; dasatinib is a prescription anticancer drug.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Related Research Articles
Published articles on this site that mention Quercetin or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.